• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

组蛋白去乙酰化酶与组蛋白去乙酰化酶抑制剂:在多种癌症中的分子作用机制

Histone Deacetylases and Histone Deacetylase Inhibitors: Molecular Mechanisms of Action in Various Cancers.

作者信息

Sanaei Masumeh, Kavoosi Fraidoon

机构信息

Research Center for Noncommunicable Diseases, Jahrom University of Medical Sciences, Jahrom, Iran.

出版信息

Adv Biomed Res. 2019 Oct 31;8:63. doi: 10.4103/abr.abr_142_19. eCollection 2019.

DOI:10.4103/abr.abr_142_19
PMID:31737580
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6839273/
Abstract

Epigenetic modifications such as histone modification play an important role in tumorigenesis. There are several evidence that histone deacetylases (HDACs) play a key role in cancer induction and progression by histone deacetylation. Besides, histone acetylation is being accessed as a therapeutic target because of its role in regulating gene expression. HDAC inhibitors (HDACIs) are a family of synthetic and natural compounds that differ in their target specificities and activities. They affect markedly cancer cells, inducing cell differentiation, cell cycle arrest and cell death, reduction of angiogenesis, and modulation of the immune system. Here, we summarize the mechanisms of HDACs and the HDACIs in several cancers. An online search of different sources such as PubMed, ISI, and Scopus was performed to find available data on mechanisms and pathways of HDACs and HDACIs in different cancers. The result indicated that HDACs induce cancer through multiple mechanisms in various tissues. This effect can be inhibited by HDACIs which affect cancer cell by different pathways such as cell differentiation, cell cycle arrest, and cell death. In conclusion, these findings indicate that the HDACs play a major role in carcinogenesis through various pathways, and HDACIs can inhibit HDAC activity by multiple mechanisms resulting in cell cycle arrest, cell growth inhibition, and apoptosis induction.

摘要

表观遗传修饰,如组蛋白修饰,在肿瘤发生过程中发挥着重要作用。有多项证据表明,组蛋白去乙酰化酶(HDACs)通过组蛋白去乙酰化作用在癌症的诱导和进展中起关键作用。此外,由于组蛋白乙酰化在调节基因表达中的作用,它正被视为一种治疗靶点。HDAC抑制剂(HDACIs)是一类合成和天然化合物,它们在靶点特异性和活性方面存在差异。它们对癌细胞有显著影响,可诱导细胞分化、细胞周期停滞和细胞死亡,减少血管生成,并调节免疫系统。在此,我们总结了HDACs和HDACIs在几种癌症中的作用机制。通过对不同来源(如PubMed、ISI和Scopus)进行在线搜索,以查找关于HDACs和HDACIs在不同癌症中的作用机制和途径的可用数据。结果表明,HDACs通过多种机制在各种组织中诱导癌症发生。这种作用可被HDACIs抑制,HDACIs通过不同途径(如细胞分化、细胞周期停滞和细胞死亡)影响癌细胞。总之,这些发现表明,HDACs通过多种途径在致癌过程中起主要作用,而HDACIs可通过多种机制抑制HDAC活性,从而导致细胞周期停滞、细胞生长抑制和诱导细胞凋亡。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8dac/6839273/83db24957f71/ABR-8-63-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8dac/6839273/f643dcc73b11/ABR-8-63-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8dac/6839273/70fe854f1d8a/ABR-8-63-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8dac/6839273/a266aa0bd45e/ABR-8-63-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8dac/6839273/df56bd6b2ce5/ABR-8-63-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8dac/6839273/e591e2753120/ABR-8-63-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8dac/6839273/de899e67f076/ABR-8-63-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8dac/6839273/50087f374264/ABR-8-63-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8dac/6839273/83db24957f71/ABR-8-63-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8dac/6839273/f643dcc73b11/ABR-8-63-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8dac/6839273/70fe854f1d8a/ABR-8-63-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8dac/6839273/a266aa0bd45e/ABR-8-63-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8dac/6839273/df56bd6b2ce5/ABR-8-63-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8dac/6839273/e591e2753120/ABR-8-63-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8dac/6839273/de899e67f076/ABR-8-63-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8dac/6839273/50087f374264/ABR-8-63-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8dac/6839273/83db24957f71/ABR-8-63-g008.jpg

相似文献

1
Histone Deacetylases and Histone Deacetylase Inhibitors: Molecular Mechanisms of Action in Various Cancers.组蛋白去乙酰化酶与组蛋白去乙酰化酶抑制剂:在多种癌症中的分子作用机制
Adv Biomed Res. 2019 Oct 31;8:63. doi: 10.4103/abr.abr_142_19. eCollection 2019.
2
Histone Deacetylase Inhibitors, Intrinsic and Extrinsic Apoptotic Pathways, and Epigenetic Alterations of Histone Deacetylases (HDACs) in Hepatocellular Carcinoma.组蛋白去乙酰化酶抑制剂、细胞内和细胞外凋亡途径以及肝细胞癌中组蛋白去乙酰化酶(HDACs)的表观遗传改变
Iran J Pharm Res. 2021 Summer;20(3):324-336. doi: 10.22037/ijpr.2021.115105.15197.
3
Combining histone deacetylase inhibitors (HDACis) with other therapies for cancer therapy.将组蛋白去乙酰化酶抑制剂(HDACis)与其他癌症疗法联合应用。
Eur J Med Chem. 2021 Dec 15;226:113825. doi: 10.1016/j.ejmech.2021.113825. Epub 2021 Sep 4.
4
Progress in discovery and development of natural inhibitors of histone deacetylases (HDACs) as anti-cancer agents.天然组蛋白去乙酰化酶(HDAC)抑制剂作为抗癌药物的发现和发展进展。
Naunyn Schmiedebergs Arch Pharmacol. 2024 Feb;397(2):675-702. doi: 10.1007/s00210-023-02674-4. Epub 2023 Aug 24.
5
Histone deacetylase inhibitors as a novel therapeutic approach for pheochromocytomas and paragangliomas.组蛋白去乙酰化酶抑制剂作为一种治疗嗜铬细胞瘤和副神经节瘤的新方法。
Oncol Res. 2023 Feb 3;30(5):211-219. doi: 10.32604/or.2022.026913. eCollection 2022.
6
Histone deacetylases function as novel potential therapeutic targets for cancer.组蛋白去乙酰化酶作为癌症新的潜在治疗靶点发挥作用。
Hepatol Res. 2017 Feb;47(2):149-159. doi: 10.1111/hepr.12757. Epub 2016 Sep 15.
7
Exploring the role of histone deacetylase inhibitors in cancer development and therapeutic potential.探讨组蛋白去乙酰化酶抑制剂在癌症发展和治疗潜力中的作用。
J Physiol Pharmacol. 2024 Apr;75(2):117-122. doi: 10.26402/jpp.2024.2.01. Epub 2024 May 6.
8
The application of histone deacetylases inhibitors in glioblastoma.组蛋白去乙酰化酶抑制剂在胶质母细胞瘤中的应用。
J Exp Clin Cancer Res. 2020 Jul 18;39(1):138. doi: 10.1186/s13046-020-01643-6.
9
Inhibitors of HDACs--effective drugs against cancer?HDAC 抑制剂——抗癌有效药物?
Curr Cancer Drug Targets. 2010 Mar;10(2):210-28. doi: 10.2174/156800910791054149.
10
Heterocyclic Moieties as HDAC Inhibitors: Role in Cancer Therapeutics.杂环作为 HDAC 抑制剂:在癌症治疗中的作用。
Mini Rev Med Chem. 2022;22(12):1648-1706. doi: 10.2174/1389557519666211221144013.

引用本文的文献

1
Heteroaryl-Capped Hydroxamic Acid Derivatives with Varied Linkers: Synthesis and Anticancer Evaluation with Various Apoptosis Analyses in Breast Cancer Cells, Including Docking, Simulation, DFT, and ADMET Studies.具有不同连接基的杂芳基封端异羟肟酸衍生物:合成及在乳腺癌细胞中的抗癌评估与多种凋亡分析,包括对接、模拟、密度泛函理论及药物代谢动力学/药物毒性预测研究
Pharmaceuticals (Basel). 2025 Aug 1;18(8):1148. doi: 10.3390/ph18081148.
2
Targeted Degradation of Class 1 HDACs With PROTACs is Highly Effective at Inducing DLBCL Cell Death.利用PROTAC对1类组蛋白去乙酰化酶进行靶向降解在诱导弥漫性大B细胞淋巴瘤(DLBCL)细胞死亡方面非常有效。
EJHaem. 2025 Aug 12;6(4):e70127. doi: 10.1002/jha2.70127. eCollection 2025 Aug.
3

本文引用的文献

1
Epigenetics in ovarian cancer: premise, properties, and perspectives.卵巢癌中的表观遗传学:前提、特征和展望。
Mol Cancer. 2018 Jul 31;17(1):109. doi: 10.1186/s12943-018-0855-4.
2
Targeting Histone Deacetylases with Natural and Synthetic Agents: An Emerging Anticancer Strategy.靶向组蛋白去乙酰化酶的天然和合成药物:一种新兴的抗癌策略。
Nutrients. 2018 Jun 6;10(6):731. doi: 10.3390/nu10060731.
3
Overexpressed HDAC8 in cervical cancer cells shows functional redundancy of tubulin deacetylation with HDAC6.在宫颈癌细胞中过表达的 HDAC8 显示出与 HDAC6 一起对微管蛋白去乙酰化的功能冗余。
Epigenetic Drivers of Chemoresistance in Nucleobase and Nucleoside Analog Therapies.
核碱基和核苷类似物疗法中化疗耐药性的表观遗传驱动因素
Biology (Basel). 2025 Jul 9;14(7):838. doi: 10.3390/biology14070838.
4
Epigenetic dysregulation in cancer: mechanisms, diagnostic biomarkers and therapeutic strategies.癌症中的表观遗传失调:机制、诊断生物标志物及治疗策略
Med Oncol. 2025 Jul 21;42(8):359. doi: 10.1007/s12032-025-02905-z.
5
Methylation Status of the Telomerase Reverse Transcriptase Promoter in Parotid Tumours and Adjacent Parotid Gland Tissue: A Pilot Study on the Implications for Recurrence and Development of Malignancy.腮腺肿瘤及腮腺腺组织中端粒酶逆转录酶启动子的甲基化状态:关于对肿瘤复发及恶性进展影响的初步研究
Curr Oncol. 2025 May 28;32(6):312. doi: 10.3390/curroncol32060312.
6
Valproic acid induces ferroptosis and suppresses the proliferation of MDA-MB-231 cells by targeting FDFT1.丙戊酸通过靶向FDFT1诱导铁死亡并抑制MDA-MB-231细胞的增殖。
Front Pharmacol. 2025 May 14;16:1540667. doi: 10.3389/fphar.2025.1540667. eCollection 2025.
7
Virtual screening and molecular dynamics simulations identify repurposed drugs as potent inhibitors of Histone deacetylase 1: Implication in cancer therapeutics.虚拟筛选和分子动力学模拟确定了重新利用的药物作为组蛋白去乙酰化酶1的有效抑制剂:对癌症治疗的意义。
PLoS One. 2025 Jan 3;20(1):e0316343. doi: 10.1371/journal.pone.0316343. eCollection 2025.
8
A short overview of dual targeting HDAC inhibitors.双靶点组蛋白去乙酰化酶抑制剂概述
Future Med Chem. 2025 Jan;17(1):5-7. doi: 10.1080/17568919.2024.2437975. Epub 2024 Dec 8.
9
Anti-ovarian cancer migration and toxicity characteristics of a platinum(IV) pro-drug with axial HDAC inhibitor ligands in zebrafish models.在斑马鱼模型中,一种带有轴向HDAC抑制剂配体的铂(IV)前药的抗卵巢癌迁移和毒性特征。
Invest New Drugs. 2024 Dec;42(6):644-654. doi: 10.1007/s10637-024-01479-3. Epub 2024 Oct 21.
10
Histone deacetylase inhibitors: targeting epigenetic regulation in the treatment of acute leukemia.组蛋白去乙酰化酶抑制剂:靶向表观遗传调控治疗急性白血病
Ther Adv Hematol. 2024 Oct 16;15:20406207241283277. doi: 10.1177/20406207241283277. eCollection 2024.
Cell Commun Signal. 2018 May 2;16(1):20. doi: 10.1186/s12964-018-0231-4.
4
Effect of Genistein and 17-β Estradiol on the Viability and Apoptosis of Human Hepatocellular Carcinoma HepG2 cell line.金雀异黄素和17-β雌二醇对人肝癌HepG2细胞系活力和凋亡的影响
Adv Biomed Res. 2017 Dec 26;6:163. doi: 10.4103/abr.abr_53_17. eCollection 2017.
5
Effects of Genistein and Synergistic Action in Combination with Tamoxifen on the HepG2 Human Hepatocellular Carcinoma Cell Line.染料木黄酮及其与他莫昔芬联合应用对人肝癌HepG2细胞系的作用及协同作用
Asian Pac J Cancer Prev. 2017 Sep 27;18(9):2381-2385. doi: 10.22034/APJCP.2017.18.9.2381.
6
Histone deacetylase HDAC1 expression correlates with the progression and prognosis of lung cancer: A meta-analysis.组蛋白去乙酰化酶HDAC1表达与肺癌的进展及预后相关:一项荟萃分析。
Medicine (Baltimore). 2017 Aug;96(31):e7663. doi: 10.1097/MD.0000000000007663.
7
Histone deacetylase 3 overexpression in human cholangiocarcinoma and promotion of cell growth via apoptosis inhibition.组蛋白去乙酰化酶3在人胆管癌中过表达并通过抑制凋亡促进细胞生长。
Cell Death Dis. 2017 Jun 1;8(6):e2856. doi: 10.1038/cddis.2016.457.
8
Chemical and structural biology of protein lysine deacetylases.蛋白质赖氨酸脱乙酰酶的化学与结构生物学
Proc Jpn Acad Ser B Phys Biol Sci. 2017;93(5):297-321. doi: 10.2183/pjab.93.019.
9
Emerging molecular therapeutic targets for cholangiocarcinoma.胆管癌的新兴分子治疗靶点。
J Hepatol. 2017 Sep;67(3):632-644. doi: 10.1016/j.jhep.2017.03.026. Epub 2017 Apr 5.
10
Epigenetic regulation of RGS2 (Regulator of G-protein signaling 2) in chemoresistant ovarian cancer cells.RGS2(G蛋白信号调节因子2)在化疗耐药性卵巢癌细胞中的表观遗传调控
J Chemother. 2017 Jun;29(3):173-178. doi: 10.1080/1120009X.2016.1277007. Epub 2017 Jan 19.